We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Increasingly Efficient Serological Tests Developed with Electrochemiluminescence

By LabMedica International staff writers
Posted on 17 Jun 2020
Print article
Image: Schematic representation of the remote electrochemiluminescence (ECL) mechanism (Photo courtesy of University of Bologna).
Image: Schematic representation of the remote electrochemiluminescence (ECL) mechanism (Photo courtesy of University of Bologna).
Diagnostic markers, or biomarkers, are biomolecules (e.g., enzymes, proteins, peptides, and hormones) that can be measured accurately and reproducibly and can precisely predict relevant clinical outcomes or diseases in various populations.

In fact, biomarkers represent a powerful aid in clinical diagnostic and therapeutic monitoring. Therefore, detection, identification, and quantification of such molecules can translate into the development of sophisticated methods and instrumentations for analyzing clinically useful biomarkers.

Medical Chemists at the University of Bologna (Bologna, Italy) and their colleagues discovered an unexpected but highly efficient mechanistic path for electrochemiluminescence (ECL) generation close to the electrode surface (signal enhancement, 128%) using an innovative combination of ECL imaging techniques and electrochemical mapping of radical generation.

The team used through the combination of ECL and microscopy and the use of labeled microbeads, they mapped ECL generation close to the electrode surface (≤1 µm), thus revealing the contribution of an additional pathway to ECL generation, which was unobserved to date. This additional mechanism exhibits a very high efficiency, i.e., 10 times more intense than the signals measured at larger distances (>1 µm).

The scientists identified a family of alternative coreactants/additives, namely branched amines, which may lead to an advantageous overall signal enhancement. In particular, the use of N-dipropyl isobutyl amine (DPIBA) enhances the ECL signal by a maximum of 47% in a commercial immunoassay system for the quantification of several biomarkers, such as thyroid stimulating hormone (TSH), cardiac troponin T, ferritin, and immunoglobulin (Ig)M antibodies against Toxoplasma gondii (Toxo IgM) and hepatitis A (A‐HAV IgM). A series of commercially available Elecsys assays (Roche Diagnostics, Indianapolis, IN) for the detection of those specific biomarkers was used on a Roche cobas e 801 immunoassay analyzer to evaluate the effect of DPIBA on the assay performance.

Alessandra Zanut, PhD, a Physical Chemist and first author of the study, said, “From these results, we managed to identify highly efficient reactants that are able to enhance the sensitivity of this technique way beyond that currently employed for serological tests. With this technique, we obtained an ECL signal enhancement up to 128% compared to current techniques.” The study was published on May 29, 2020 in the journal Nature Communications.




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more